novan
reports
third
quarter
financial
results
provides
corporate
update
lead
product
candidate
currently
evaluated
pivotal
phase
study
molluscum
contagiosum
topline
data
targeted
first
demonstrate
antiviral
effect
nitric
medicine
vitro
model
mimics
human
airway
epithelium
exploratory
work
evaluate
antimicrobial
indications
companion
animal
health
initiated
company
actively
seeking
opportunities
leverage
broader
pipeline
secure
next
phase
growth
morrisville
globe
newswire
novan
company
novan
nasdaq
novn
today
announced
financial
results
quarter
ended
september
provided
corporate
update
last
months
marked
many
significant
achievements
company
advancement
priority
development
pipeline
initiated
pivotal
phase
study
even
current
global
pandemic
pleased
report
enrollment
remained
track
targeted
complete
first
quarter
also
recently
reported
positive
vitro
results
demonstrating
antiviral
effect
nitricil
platform
coronavirus
next
step
would
advance
program
preclinical
studies
additionally
taken
deliberate
actions
strengthen
balance
sheet
believe
sufficient
capital
fund
operations
fourth
quarter
commented
paula
brown
stafford
president
chief
executive
officer
novan
recent
highlights
initiated
enrollment
dosed
first
patients
pivotal
phase
study
topical
antiviral
gel
treatment
molluscum
demonstrated
vitro
antiviral
effect
proprietary
technology
human
airway
infection
commenced
exploratory
work
evaluate
antimicrobial
indications
companion
animal
health
continued
ongoing
review
existing
programs
opportunities
expand
priority
development
pipeline
announced
appointment
john
gay
serve
company
chief
financial
officer
appointment
james
bierman
company
board
directors
announced
expanded
role
paula
brown
stafford
president
chief
executive
officer
novan
also
include
chairman
novan
board
directors
since
january
secured
approximately
million
capital
multiple
sources
including
use
common
stock
purchase
agreements
aspire
capital
fund
llc
march
public
offering
exercise
related
common
stock
warrants
march
registered
direct
offering
past
months
raised
capital
progress
lead
asset
molluscum
provide
expected
cash
runway
past
targeted
topline
results
trial
maintaining
listing
nasdaq
remains
critical
priority
company
continue
pursue
course
action
intended
allow
us
work
toward
regaining
compliance
manner
believe
best
interests
company
stockholders
commented
john
gay
chief
financial
officer
recognizing
importance
process
stockholders
expect
provide
update
matter
priority
development
pipeline
update
topical
antiviral
treatment
viral
skin
infections
molluscum
contagiosum
company
commenced
patient
enrollment
dosing
september
randomized
study
expected
enroll
approximately
patients
randomization
across
clinical
sites
treated
weeks
visit
week
company
completed
total
expected
patient
enrollment
study
upcoming
targeted
milestones
completion
enrollment
targeted
topline
efficacy
results
targeted
trial
impacted
pandemic
information
trial
please
visit
reference
identifier
infectious
disease
coronaviridae
company
initiated
vitro
assessments
targeting
reduction
viral
burden
differentiated
normal
human
bronchial
epithelial
cells
studies
conducted
institute
antiviral
research
utah
state
university
results
demonstrate
first
instance
antiviral
effect
nitric
medicine
tissue
model
similar
structure
human
airway
epithelium
results
vitro
assessment
concentrations
low
mg
ml
demonstrated
berdazimer
sodium
reduced
virus
repeat
dosing
daily
upcoming
targeted
milestones
initiate
chemistry
manufacturing
controls
cmc
work
global
leader
providing
integrated
services
superior
delivery
technologies
manufacturing
solutions
develop
intranasal
formulation
berdazimer
sodium
companion
animal
health
novan
initiated
exploratory
work
evaluate
company
new
chemical
entity
potential
product
candidate
antimicrobial
indications
companion
animal
health
additionally
company
engaged
animal
health
experts
assess
technical
feasibility
market
potential
upcoming
targeted
milestones
currently
intend
seek
potential
strategic
partner
collaborator
following
initial
work
financial
update
summary
financial
results
third
quarter
novan
reported
net
loss
million
three
months
ended
september
compared
million
net
loss
period
september
novan
total
cash
cash
equivalents
balance
million
positive
working
capital
million
company
believes
existing
cash
cash
equivalents
balance
september
expected
contractual
payments
received
connection
existing
licensing
agreements
provide
adequate
liquidity
fund
operating
needs
fourth
quarter
based
management
projections
planned
priority
development
activities
described
company
quarterly
report
form
three
month
period
ended
september
summary
financial
results
september
novan
reported
net
loss
million
nine
months
ended
september
compared
million
net
loss
period
license
collaboration
revenue
million
nine
months
ended
september
compared
million
period
associated
company
performance
period
related
amortization
upfront
expected
milestone
payments
one
company
license
agreements
research
development
expenses
million
nine
months
ended
september
compared
million
period
decrease
primarily
attributable
net
decreased
costs
million
related
novan
relative
timing
trial
enrollment
initiation
occurred
late
third
quarter
compared
enrollment
initiations
previous
phase
trials
occurred
late
second
quarter
ii
decrease
million
research
development
expenses
primarily
related
million
net
decrease
research
development
personnel
costs
million
decrease
costs
primarily
associated
manufacturing
technology
transfer
projects
manufacturers
general
administrative
expenses
million
nine
months
ended
september
compared
million
period
increase
primarily
due
million
expense
related
issuance
commitment
shares
consideration
entering
common
stock
purchase
arrangements
aspire
capital
partially
offset
million
decrease
general
administrative
personnel
related
costs
nine
months
ended
september
company
recognized
million
impairment
charges
related
july
termination
previous
primary
facility
lease
million
loss
disposition
related
assets
million
charge
novan
novan
clinical
biotechnology
company
focused
leveraging
proprietary
nitric
oxide
based
technology
platform
generate
macromolecular
new
chemical
entities
nces
treat
multiple
indications
dermatology
men
women
health
infectious
diseases
gastroenterology
conditions
significant
unmet
needs
company
lead
product
candidate
topical
antiviral
gel
treatment
molluscum
contagiosum
currently
evaluated
pivotal
phase
clinical
study
company
believes
topical
therapy
rapid
treatment
benefit
approved
would
address
important
need
treatment
molluscum
statements
statements
contained
press
release
describe
historical
facts
may
constitute
statements
term
defined
private
securities
litigation
reform
act
statements
may
identified
words
believe
expect
may
plan
potential
similar
expressions
based
company
current
beliefs
expectations
statements
include
limited
statements
related
potential
therapeutic
value
company
platform
technology
company
pharmaceutical
development
nitric
product
candidates
company
intention
advance
development
certain
product
candidates
company
expected
cash
runway
company
plans
regain
compliance
nasdaq
listing
standards
company
intention
partner
third
parties
statements
subject
number
risks
uncertainties
could
cause
actual
results
differ
materially
company
expectations
including
limited
risks
uncertainties
company
ongoing
future
product
development
activities
preclinical
studies
may
prove
successful
demonstrating
concept
may
show
adverse
toxicological
findings
even
successful
may
necessarily
predict
subsequent
clinical
trials
show
requisite
safety
efficacy
company
product
candidates
company
ability
enter
arrangements
third
parties
support
development
efforts
terms
acceptable
company
risks
uncertainties
clinical
development
process
including
among
others
length
expense
ability
enroll
patients
reliance
third
parties
potential
delays
impacts
whether
result
pandemic
factors
results
earlier
research
preclinical
clinical
trials
may
predictive
results
conclusions
interpretations
later
research
activities
additional
trials
risks
related
regulatory
approval
process
lengthy
inherently
unpredictable
including
risk
company
product
candidates
may
approved
additional
studies
may
required
approval
delays
may
occur
company
may
obtain
funding
sufficient
complete
regulatory
development
process
company
ability
obtain
additional
funding
enter
strategic
business
relationships
necessary
useful
development
company
product
candidates
risk
disruptions
fda
agencies
could
cause
agencies
cancel
postpone
meetings
otherwise
impact
ability
agencies
provide
regulatory
guidance
feedback
timely
review
process
company
regulatory
submissions
could
material
adverse
effect
company
business
risks
related
manufacture
raw
materials
including
company
active
pharmaceutical
ingredient
drug
product
components
utilized
clinical
trial
materials
including
failure
transfer
technology
processes
third
parties
effectively
failure
third
parties
obtain
approval
maintain
compliance
fda
comparable
regulatory
authorities
operational
disruptions
result
pandemic
including
delays
disruptions
enrollment
conduct
phase
trial
risks
uncertainties
described
company
annual
report
filed
sec
form
twelve
months
ended
december
amended
company
subsequent
filings
sec
including
company
quarterly
report
form
three
months
ended
september
statements
speak
date
press
release
novan
disclaims
intent
obligation
update
statements
reflect
events
circumstances
date
statements
except
may
required
law
novan
condensed
consolidated
statements
operations
comprehensive
loss
unaudited
thousands
except
share
per
share
amounts
three
months
ended
september
nine
months
ended
september
license
collaboration
revenue
government
research
contracts
grants
revenue
total
revenue
operating
expenses
research
development
general
administrative
impairment
loss
assets
loss
facility
asset
group
disposition
total
operating
expenses
operating
loss
expense
income
net
interest
income
interest
expense
expense
income
total
expense
income
net
net
loss
comprehensive
loss
net
loss
per
share
basic
diluted
common
shares
outstanding
basic
diluted
novan
inc
selected
condensed
consolidated
balance
sheet
data
unaudited
thousands
september
december
cash
cash
equivalents
total
current
assets
total
assets
total
current
liabilities
total
liabilities
total
stockholders
equity
deficit
total
liabilities
stockholders
equity
deficit
investor
media
contact
jenene
thomas
jtc
team
llc
novn
